Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Ligand Pharmaceuticals (LGND) Debt to Equity: 2011-2025

Historic Debt to Equity for Ligand Pharmaceuticals (LGND) over the last 5 years, with Sep 2025 value amounting to $0.47.

  • Ligand Pharmaceuticals' Debt to Equity was N/A to $0.47 in Q3 2025 from the same period last year, while for Sep 2025 it was $0.47, marking a year-over-year change of. This contributed to the annual value of $0.13 for FY2022, which is N/A change from last year.
  • According to the latest figures from Q3 2025, Ligand Pharmaceuticals' Debt to Equity is $0.47, which was up 294.62% from $0.12 recorded in Q1 2023.
  • In the past 5 years, Ligand Pharmaceuticals' Debt to Equity registered a high of $0.47 during Q3 2025, and its lowest value of $0.09 during Q3 2022.
  • Over the past 2 years, Ligand Pharmaceuticals' median Debt to Equity value was $0.29 (recorded in 2025), while the average stood at $0.29.